Paris – Médecins Sans Frontières / Doctors Without Borders (MSF), together with its partners, is happy to announce that the endTB clinical trials have started in India.
Results from the endTB Observational Study were published July 24, 2020, in the American Journal of Respiratory and Critical Care Medicine.
After a first meeting in 2018, Médecins Sans Frontières, Sponsor of the endTB Clinical Trials, and its partners (PIH, IRD, HMS, ITM and Epicentre) have gathered for the second time the endTB Clinical Trial investigators and study coordinators in Paris.
Karachi / Paris – Médecins Sans Frontières / Doctors Without Borders (MSF) and Interactive Research and Development (IRD) are pleased to announce the start of the endTB clinical trial in Pakistan.
In March 2019, the endTB clinical trial celebrated a major milestone: the first participant completed participation in the trial. The patient, diagnosed with rifampin-resistant tuberculosis (RR-TB), started treatment and study participation in March 2017 in Tbilisi, Georgia.
endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris.
Limpho Taka, a 47-year old patient with HIV and multidrug-resistant TB, (MDR-TB) lives in Mpokochela, a village in the Drakenberg mountains of Lesotho. It takes him three hours on his horse to reach the Bobete clinic where he receives treatment for MDR-TB.
Médecins Sans Frontières / Doctors Without Borders (MSF) announces the closure of patient enrollment in the endTB clinical trial in Georgia.
Georgia continues to struggle with tuberculosis (TB), today’s leading infectious disease killer, and its drug-resistant forms. The homeless, unemployed, migrants, prisoners, and people who excessively consume alcohol are among the most affected.
Attending the UNION conference in Guadalajara (11-14 October)?
Don’t miss these events from endTB and partners.
Yury, 38, is celebrating a moment he thought would never arrive: he has been cured of a complicated form of Tuberculosis (TB), an infectious disease caused by mycobacteria which usually attacks the lungs.
For the first time in 50 years, two new drugs are available to patients battling the most trenchant forms of tuberculosis.